LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

Search

Pliant Therapeutics Inc

Gesloten

1.28 4.92

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.16

Max

1.29

Belangrijke statistieken

By Trading Economics

Inkomsten

17M

-26M

EPS

-0.43

Winstmarge

-2,190.837

Werknemers

171

EBITDA

19M

-23M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+147.93% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-8.5M

94M

Vorige openingsprijs

-3.64

Vorige sluitingsprijs

1.28

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Pliant Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 dec 2025, 23:48 UTC

Belangrijke Marktbewegers

Shares of Sezzle and Vital Farms Rise on S&P SmallCap 600 Inclusion

8 dec 2025, 23:44 UTC

Marktinformatie

Perky Australian Dollar Looks to Extend Gains -- Market Talk

8 dec 2025, 23:42 UTC

Marktinformatie

Nikkei May Decline Amid Uncertainty Over Econ, Earnings -- Market Talk

8 dec 2025, 23:13 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

8 dec 2025, 23:13 UTC

Marktinformatie

Australian Inflation Expectations Highest Since Late 2023 -- Market Talk

8 dec 2025, 23:09 UTC

Acquisities, Fusies, Overnames

Paramount Made a Hostile Bid for Warner After Netflix Deal. What Happens Next? -- WSJ

8 dec 2025, 22:46 UTC

Marktinformatie

Rio Tinto Building Low-Cost Lithium Business in Difficult Market -- Market Talk

8 dec 2025, 22:01 UTC

Marktinformatie

Miners Poised to Do Well in 2026 -- Market Talk

8 dec 2025, 22:00 UTC

Acquisities, Fusies, Overnames

Noble: Agreement With Borr Includes Sale of Noble Tom Prosser, Noble Mick O'Brien, Noble Regina Allen, Noble Resilient, Noble Resolute, Closing Expected in Early 2026 >NE

8 dec 2025, 22:00 UTC

Acquisities, Fusies, Overnames

Noble: Agreement With Borr Comprises $210M in Cash and $150M in Seller Notes >NE

8 dec 2025, 22:00 UTC

Acquisities, Fusies, Overnames

Noble: Agreement With Ocean Oilfield Drilling Anticipates the Sale of the Noble Resolve, Closing Is Expected in 2Q 2026, Upon Conclusion of Noble Resolve's Current Contract >NE

8 dec 2025, 22:00 UTC

Acquisities, Fusies, Overnames

Noble: To Sell Five Rigs to Borr Drilling Limited for $360M and One Rig to Ocean Oilfield Drilling for $64M in Cash >NE

8 dec 2025, 21:51 UTC

Marktinformatie

US-Canada Rate Spreads Narrow Sharply After Record Gap -- Market Talk

8 dec 2025, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

8 dec 2025, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

8 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 dec 2025, 21:38 UTC

Acquisities, Fusies, Overnames

Boeing Buys Company Responsible for Door Blowout. The Stock Rises. -- Barrons.com

8 dec 2025, 21:38 UTC

Acquisities, Fusies, Overnames

Paramount Makes $77.9 Billion Hostile Bid for Warner After Netflix Struck Deal -- 7th Update

8 dec 2025, 21:36 UTC

Marktinformatie

Oil Oversupply to Show Up As Waterborne Stocks Land -- Market Talk

8 dec 2025, 21:20 UTC

Acquisities, Fusies, Overnames

Will the Netflix-Warner Bros. Merger Go Through? It Depends on How You Define Market Share. -- Barrons.com

8 dec 2025, 21:12 UTC

Acquisities, Fusies, Overnames

These Stocks Moved the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

8 dec 2025, 21:08 UTC

Marktinformatie

Rosenberg Turns 'Outright Bullish' on Canada Dollar -- Market Talk

8 dec 2025, 20:38 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Netflix Co-CEOs Confident About Regulatory Approval for WBD Deal -- Market Talk

8 dec 2025, 20:26 UTC

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

8 dec 2025, 20:18 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Netflix Isn't Looking to Make Cuts at Warner Bros. Discovery -- Market Talk

8 dec 2025, 20:07 UTC

Marktinformatie

Oil Futures Snap Three-Session Winning Streak -- Market Talk

8 dec 2025, 20:06 UTC

Marktinformatie

U.S. Natural Gas Pulls Back From Weather-Driven Highs -- Market Talk

8 dec 2025, 20:05 UTC

Marktinformatie

Global Equities Roundup: Market Talk

8 dec 2025, 20:05 UTC

Marktinformatie

Deere Offers Sales Growth Forecast Through 2030 -- Market Talk

8 dec 2025, 20:01 UTC

Marktinformatie

Precious Metals Slip Ahead of Fed Decision -- Market Talk

Peer Vergelijking

Prijswijziging

Pliant Therapeutics Inc Prognose

Koersdoel

By TipRanks

147.93% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 3 USD  147.93%

Hoogste 4 USD

Laagste 2 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pliant Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

4 ratings

0

Buy

3

Hold

1

Sell

Technische score

By Trading Central

1.43 / 1.6Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
help-icon Live chat